Stephen obtained his PhD in Molecular Biology at Imperial College, London, before moving on to postdoctoral positions in Australia. He first identified the genes required for development of the Drosophila brain and then generated one of the first mouse models of cystic fibrosis with the same mutation as found in humans. This was followed by work on gene therapy for cystic fibrosis in a collaboration between Boehringer Ingelheim and the Medical Research Council (MRC) Human Genetics Unit in Edinburgh. Stephen joined AstraZeneca as a Team Leader in 1997 and has provided support for many drug discovery projects around target identification, validation and reagent generation. He has also been a project leader for several small molecule and biologics project teams. In 2002, he became a Principal Scientist and in 2011 moved to Gothenburg, as part of the formation of the iMed for Respiratory and Inflammation and Autoimmunity. Since moving to Gothenburg, he has led teams carrying out target validation and biomarker discovery.